We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

51 hedge funds and large institutions have $483M invested in Fusion Pharmaceuticals Inc. Common Shares in 2020 Q2 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
51
Holders Change
+51
Holders Change %
–
% of All Funds
1.05%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
51
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JJIJ
Johnson & Johnson Innovation - JJDC
New Jersey
+$63.9M
2
ASP
Adams Street Partners
Illinois
+$61M
3
O
OrbiMed
New York
+$56.2M
4
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
+$54.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$52.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$1.32M +$1.32M +75,600 New
AllianceBernstein
27
AllianceBernstein
Tennessee
$1.31M +$1.31M +75,000 New
Blackstone Inc
28
Blackstone Inc
New York
$1.05M +$1.05M +60,000 New
CCM
29
CAAS Capital Management
New York
$1.05M +$1.05M +60,000 New
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$1.05M +$1.05M +60,000 New
MIM
31
Monashee Investment Management
Massachusetts
$874K +$871K +50,000 New
Norges Bank
32
Norges Bank
Norway
$874K +$871K +50,000 New
Tudor Investment Corp
33
Tudor Investment Corp
Connecticut
$509K +$508K +29,145 New
MS
34
Maven Securities
Jersey
$437K +$435K +25,000 New
PAMU
35
Pictet Asset Management (UK)
United Kingdom
$401K +$400K +22,973 New
ZP
36
Zimmer Partners
New York
$393K +$392K +22,500 New
Wells Fargo
37
Wells Fargo
California
$271K +$270K +15,517 New
DKCM
38
Davidson Kempner Capital Management
New York
$263K +$261K +15,000 New
CM
39
Crestline Management
Texas
$175K +$174K +10,000 New
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$175K +$174K +10,000 New
PHK
41
Point72 Hong Kong
Hong Kong
$140K +$140K +8,019 New
UBS Group
42
UBS Group
Switzerland
$96K +$95.5K +5,484 New
SCM
43
Sio Capital Management
New York
$52K +$52.3K +3,000 New
PE
44
Point72 Europe
United Kingdom
$35K +$34.8K +2,000 New
AA
45
AlphaCentric Advisors
Puerto Rico
$31K +$31.4K +1,800 New
Legal & General Group
46
Legal & General Group
United Kingdom
$18K +$17.4K +1,000 New
PAM
47
Panagora Asset Management
Massachusetts
$17K +$17.4K +1,000 New
PCM
48
Pinz Capital Management
New York
$12K +$12.2K +700 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$5K +$5.22K +300 New
S
50
SignatureFD
Georgia
$5K +$5.22K +300 New
1
2
3

FUSN Hedge Fund Activity: Q2 2020 in Review

51 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2020, worth a combined $483M.

Buyers outnumbered sellers: 51 funds opened new FUSN positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Johnson & Johnson Innovation - JJDC, opening a new position worth an estimated $63.9M.

  • 51 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2020, up from 0 in Q1 2020.
  • Funds reported $483M of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2020.
  • 51 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2020 and 0 closed out, a net change of +51 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q2 2020 was Johnson & Johnson Innovation - JJDC, an estimated $63.9M added.

Based on aggregated 13F filings for Q2 2020.